$0.05
(Market cap
$5 Mln
Recently Viewed
Clear AllMarket cap
$5 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
7.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$4 Mln
ROE
-56 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-2.1
Debt to Equity
-3.3
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
3,651,930
CFO
$-280.29 Mln
EBITDA
$-184.66 Mln
Net Profit
$-261.67 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BiondVax Pharmaceuticals - ADR
| -76.7 | -9.8 | -48.5 | -91.7 | -70.4 | -58.1 | -- |
|
BSE Sensex*
| -7.3 | 5.3 | -4.1 | -1.1 | 9.6 | 10.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
BiondVax Pharmaceuticals - ADR
| -87.4 | -16.4 | -69.8 | 94.8 | -11.0 | 60.0 | -15.4 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BiondVax Pharmaceuticals - ADR
|
0.7 | 5.0 | 2.0 | 17.2 | -618.4 | -- | -- | 7.5 |
| 1.3 | 70.1 | 0.0 | -37.0 | -- | -98.4 | -- | 0.5 |
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel.... The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel. Read more
CEO & Director
Mr. Amir Reichman M.B.A., M.Sc.
CEO & Director
Mr. Amir Reichman M.B.A., M.Sc.
Headquarters
Jerusalem
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of BiondVax Pharmaceuticals Ltd - ADR is $0.69 (NASDAQ) as of 08-Nov-2023 09:30 EDT. BiondVax Pharmaceuticals Ltd - ADR has given a return of -70.43% in the last 3 years.
Since, TTM earnings of BiondVax Pharmaceuticals Ltd - ADR is negative, P/E ratio is not available.
The P/B ratio of BiondVax Pharmaceuticals Ltd - ADR is 7.48 times as on 08-Nov-2023, a 64 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of BiondVax Pharmaceuticals Ltd - ADR are Rs -- and Rs -- as of 22-Apr-2026.
BiondVax Pharmaceuticals Ltd - ADR has a market capitalisation of $ 5 Mln as on 08-Nov-2023. As per SEBI classification, it is a Small Cap company.
Before investing in BiondVax Pharmaceuticals Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.